Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial

被引：0
|
作者：
Binghe Xu
Zefei Jiang
Zhimin Shao
Jiayu Wang
Jifeng Feng
Shuping Song
Zhendong Chen
Kangsheng Gu
Shiying Yu
Yiping Zhang
Chuan Wang
Fengchun Zhang
Junlan Yang
机构：
[1] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Medical Oncology, Cancer Hospital and Institute
[2] Beijing 307 Hospital,Cancer Hospital and Shanghai Cancer Institute
[3] Fudan University,First Affiliated Hospital
[4] Jiangsu Cancer Hospital,Tongji Hospital
[5] Shandong Cancer Hospital,Affiliated Union Hospital
[6] Anhui Medical University,Renji Hospital
[7] Huizhong Science and Technique University,undefined
[8] Zhejiang Cancer Hospital,undefined
[9] Fujian Medical University,undefined
[10] Shanghai Jiaotong University,undefined
[11] 301 Hospital,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Advanced breast cancer; Anastrozole; Arimidex; China; Faslodex; Fulvestrant; Oestrogen receptor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：223 / 230
页数：7
相关论文
共 50 条
  • [41] Radiotherapy for Ledderhose disease: Results of the LedRad-study, a prospective multicentre randomised double-blind phase 3 trial
    de Haan, Anneke
    van Nes, Johanna G. H.
    Kolff, M. Willemijn
    van der Toorn, Peter-Paul
    Westenberg, A. Helen
    van der Vegt, Annelies E.
    Groen, Henk
    Overbosch, Jelle
    van der Laan, Hans Paul
    Werker, Paul M. N.
    Langendijk, Johannes A.
    Steenbakkers, Roel J. H. M.
    RADIOTHERAPY AND ONCOLOGY, 2023, 185
  • [42] Comparison of Fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial
    Howell, A
    Robertson, JE
    Abram, P
    Lichinitser, MR
    Elledge, R
    Bajetta, E
    Watanabe, T
    Morris, C
    Webster, A
    Dimery, I
    Osborne, CK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) : 1605 - 1613
  • [43] Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
    Leboulleux, Sophie
    Bastholt, Lars
    Krause, Thomas
    de la Fouchardiere, Christelle
    Tennvall, Jan
    Awada, Ahmad
    Manuel Gomez, Jose
    Bonichon, Francoise
    Leenhardt, Laurence
    Soufflet, Christine
    Licour, Muriel
    Schlumberger, Martin J.
    LANCET ONCOLOGY, 2012, 13 (09): : 897 - 905
  • [44] Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
    Kuse, Ernst-Ruediger
    Chetchotisakd, Ploenchan
    da Cunha, Clovis Arns
    Ruhnke, Markus
    Barrios, Carlos
    Raghunadharao, Digumarti
    Sekhon, Jagdev Singh
    Freire, Antonio
    Ramasubramanian, Venkatasubramanian
    Demeyer, Ignace
    Nucci, Marcio
    Leelarasamee, Amorn
    Jacobs, Frederique
    Decruyenaere, Johan
    Pittet, Didier
    Ullmann, Andrew J.
    Ostrosky-Zeichner, Luis
    Lortholary, Olivier
    Koblinger, Sonja
    Diekmann-Berndt, Heike
    Cornely, Oliver A.
    LANCET, 2007, 369 (9572): : 1519 - 1527
  • [45] Citalopram versus fluoxetine: A double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice
    Patris, M
    Bouchard, JM
    Bougerol, T
    Charbonnier, JF
    Chevalier, JF
    Clerc, G
    Cyran, C
    VanAmerongen, P
    Lemming, O
    Petersen, HEH
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1996, 11 (02) : 129 - 136
  • [46] A Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Postmenopausal Women with Metastatic Breast Cancer: SWOG S0226
    Mehta, R. S.
    Barlow, W. E.
    Albam, K. S.
    Vandenberg, T.
    Dakhil, S. R.
    Tirumali, N. R.
    Lew, D. L.
    Hayes, D. F.
    Gralow, J. R.
    Livingston, R. B.
    Hortobagyi, G. N.
    CANCER RESEARCH, 2011, 71
  • [47] Rituximab in patients with primary progressive multiple sclerosis: demographics in a Phase II/III randomised, double-blind, placebo-controlled multicentre trial
    Hawker, K.
    Freedman, M. S.
    O'Connor, P.
    Calabresi, P.
    Antel, J. P.
    Pallitch, H.
    Simon, J.
    Hauser, S.
    Sarkar, N.
    Agarwal, S.
    Langer-Gould, A.
    Smith, C.
    MULTIPLE SCLEROSIS, 2007, 13 : S165 - S165
  • [48] Results of the randomized phase II trial of adjuvant anastrozole versus anastrozole plus fulvestrant in hormone-receptor-positive postmenopausal breast cancer patients with bone marrow micrometastasis (ABCSG trial 21).
    Braun, S.
    Naume, B.
    Mueller, E.
    Janni, W.
    Marth, C.
    Gnant, M. F.
    CANCER RESEARCH, 2009, 69 (02) : 297S - 298S
  • [49] Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
    Kaufmann, M
    Bajetta, E
    Dirix, LY
    Fein, LE
    Jones, SE
    Zilembo, N
    Dugardyn, JC
    Nasurdi, C
    Mennel, RG
    Cervek, J
    Fowst, C
    Polli, A
    di Salle, E
    Arkhipov, A
    Piscitelli, G
    Miller, LL
    Massimini, G
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (07) : 1399 - 1411
  • [50] Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial
    Jones, R.
    Casbard, A.
    Carucci, M.
    Smith, J.
    Ingarfield, K.
    Gee, J. M. W.
    Hudson, Z.
    Alchami, F.
    Hayward, L.
    Hickish, T.
    Hwang, D.
    McAdam, K.
    Spensley, S.
    Waters, S.
    Wheatley, D.
    Beresford, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1151 - S1151
12345